文献速递真菌感染

接受体外膜氧合的危重症患者中艾沙康唑的血浆浓度

Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究纳入7例接受体外膜氧合(ECMO)的危重症患者,在标准剂量静脉艾沙康唑首次给药后2至168小时采集64份血样,并额外从膜氧合器流入与流出管路采集27份血样。结果显示,首次给药后24小时或96小时中位谷浓度分别超过1 μg/mL(最小0.83,最大1.73)或2 μg/mL(最小0.84,最大2.97);膜氧合器前后浓度直接相关(ρ=0.987,R2=0.994,P<0.001)。作者认为艾沙康唑浓度可能受ECMO治疗分布容积增大影响,但未被膜氧合器改变,首次负荷剂量后24小时达到中位血浆浓度>1 μg/mL。

要点

  • 7例ECMO危重症患者标准剂量静脉艾沙康唑,首次给药后24小时中位谷浓度>1 μg/mL。
  • 首次给药后96小时中位谷浓度>2 μg/mL。
  • 膜氧合器流入与流出管路浓度直接相关,ρ=0.987。

核心结论

  • 艾沙康唑浓度可能受ECMO治疗分布容积增大影响,但未被ECMO氧合器改变,首次负荷剂量后24小时达到中位血浆浓度>1 μg/mL。

研究设计与样本

  • 研究纳入7例接受标准剂量静脉艾沙康唑和ECMO的危重症患者。
  • 首次艾沙康唑给药后2小时起至168小时多个时间点采集64份血样测浓度。
  • 另从膜氧合器流入和流出管路采集27份血样评估ECMO氧合装置及管路的潜在清除效应。

主要发现

  • 首次给药后24小时中位艾沙康唑谷浓度>1 μg/mL(最小0.83,最大1.73)。
  • 首次给药后96小时中位艾沙康唑谷浓度>2 μg/mL(最小0.84,最大2.97)。
  • 膜氧合器前(流入管路)与后(流出管路)艾沙康唑血浆浓度直接相关(ρ=0.987,R2=0.994,P<0.001)。
  • 膜氧合器后艾沙康唑浓度与同期患者动脉管路样本直接相关(ρ=0.942,R2=0.945,P<0.001)。

临床怎么用

  • 作者认为艾沙康唑浓度可能受ECMO治疗分布容积增大影响,但未被ECMO氧合器改变,首次负荷剂量后24小时达到中位血浆浓度>1 μg/mL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isavuconazole is an antifungal drug used for treatment of invasive fungal infections. Critically ill COVID-19 and influenza patients require extracorporeal membrane oxygenation (ECMO) in cases with severe acute respiratory distress syndrome and have risk factors for invasive pulmonary aspergillosis. Little is known about isavuconazole plasma concentrations during ECMO. OBJECTIVES: To determine isavuconazole plasma concentrations in seven patients treated with intravenous isavuconazole under ECMO and the influence of the ECMO circuit immediately after the first isavuconazole dose. METHODS: Critically ill patients treated with isavuconazole (standard doses) and ECMO were included in this study. Sixty-four blood samples used for measurement of isavuconazole concentrations were collected at several timepoints starting 2 h after the first isavuconazole dose up to 168 h. An additional 27 blood samples were drawn from the inflow and outflow line of the membrane oxygenator to assess any potential isavuconazole clearance effect of the ECMO oxygenation device and the lines. RESULTS: Median isavuconazole trough levels above 1 μg/mL (min. 0.83, max. 1.73) or 2 μg/mL (min. 0.84, max. 2.97) were achieved 24 h or 96 h after the first dose of isavuconazole. The isavuconazole plasma concentrations pre (inflow line) and post (outflow line) the membrane oxygenator were directly correlated (ρ = 0.987, R2 = 0.994, P < 0.001). Post membrane oxygenator isavuconazole concentrations were directly correlated to contemporaneous samples obtained from the arterial lines of patients (ρ = 0.942, R2 = 0.945, P < 0.001). CONCLUSIONS: Isavuconazole concentrations might be influenced by the higher volume of distribution due to ECMO therapy, but were not altered by the ECMO oxygenator and achieved median plasma concentrations >1 μg/mL 24 h after the first loading dose.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kriegl L, Hatzl S, Zurl C, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022. PMID: 35726095. doi:10.1093/jac/dkac196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。